Case 2
In April 2002 a 69 year old white woman with diffuse systemic sclerosis (SSc), diagnosed in 2001, was admitted to hospital after a 6 month history of dyspnoea on exertion (NYHA II/III), fatigue, chest pain, and dry cough. Physical examination showed diffuse teleangiectasias, cyanosis of the lips and fingers, mild oedema of the feet, crackles in lower lobes, pansystolic murmur (4/6 L) on the apex, with accentuation of the pulmonary component of the second heart sound; the liver was enlarged with mild ascites.
Laboratory testing showed an erythrocyte sedimentation rate of 31 mm/1st h; prothrombin time 20 seconds (normal ,15 seconds), and activated partial prothrombin time 41 seconds ( normal 26-36 seconds). Antinuclear antibodies were positive (1/5120). A chest x ray showed cardiomegaly without interstitial involvement. FVC was normal (84%), with a significant decrease of carbon monoxide transfer factor TLCO (36%), severe hypoxaemia and respiratory alkalosis (partial pressure of oxygen 62.6 mm Hg; partial pressure of carbon dioxide 28 mm Hg; HCO 3 2 20.7 mmol/l; arterial oxygen saturation 90%). Chest high resolution CT showed an enlarged right atrium and ventricle, dilatation of the main pulmonary artery, centralisation of pulmonary vascular flow with pulmonary congestion, bilateral pleural effusion, and pericardial effusion. Bibasilar mild ground glass opacities were detected. A Doppler echocardiogram showed enlargement of the right heart with tricuspid insufficiency, paradoxical movement of the cardiac septum, mild pericardial effusion, and raised PASP (70 mm Hg).
Right N This is a case of limited cutaneous SSc. In such a case, when the patient complains of breathlessness, interstitial involvement or vascular lung disease, or both, should be suspected, both leading to PAH and respiratory failure. 1 In this case, PAH was secondary to interstitial lung disease, as indicated by a reduced FCV and the CT scan and was exacerbated by a pulmonary thromboembolic event due to antiphospholipid syndrome. The relationship between PAH and interstitial disease is confirmed by the results of the treatment with CYC, which significantly improved the FVC and PASP.
Comment
This case shows that some important investigations, that might have added significant information for a more precise management, are missing: N Carbon monoxide transfer factor (TLCO) is missing. It measures gas exchange at the level of the alveolocapillary membrane and identifies impairment of the transfer of CO that may be due to interstitial fibrosis or vascular disease. In particular, the FVC/TLCO ratio may be helpful in a differential diagnosis for PAH complicating SSc, with an FVC/TLCO ratio .1.4 indicating a vascular pulmonary hypertension. Accordingly, an isolated decrease of TLCO, with a normal FVC, is a reliable marker for the development of PAH in SSc. [1] [2] [3] In SSc, a severe reduction in TLCO (,40% of predicted values) is indeed an adverse prognostic factor. 4 For this reason, pulmonary function tests with TLCO are a fundamental investigation in assessment of the patient with SSc. 5 N Right heart catheterisation with vasodilator test. When the clinical assessment and the echo Doppler measurement indicate PAH then right heart catheterisation is mandatory. It allows the ''mean pulmonary artery pressure'' to be determined. Also, assessment of other indices such as right atrial and ventricular pressures, pulmonary capillary wedge pressure, and cardiac output is essential for differential diagnosis of PAH secondary to myocardial disease and has important prognostic value. Catheterisation makes it possible to verify if PAH is postcapillary, which is seldom the case in patients with SSc. A vasodilator test is necessary to evaluate the response of pulmonary vasculature in order to identify those patients who may benefit from the use of calcium channel blocker or other drugs, 3 6 although the frequency of true responders is low in scleroderma and the benefits of high dose calcium channel blockers must be balanced against potential toxicity.
N Helical spiral CT angiography is indicated for further diagnosis and localisation of thromboembolic disease, especially when surgical intervention is considered for embolectomy. 7 N An exercise test (6 minute walk test) is recommended in patients with PAH at the time of diagnosis and for the follow up, to characterise the functional impairment and the response to treatment. 3 6 The case was well managed, but N Anticoagulation should be recommended in all cases of thromboembolic PAH and in all other types of arterial PAH unless contraindicated 5 8 N Oxygen treatment is indeed recommended in all cases of PAH with hypoxaemia. In this case, basal therapy is needed: first of all it is necessary to anticoagulate (reach an INR of between 2 and 3), use oxygen (2 litres/min) that may be highly helpful, as well as diuretics. If during catheterisation the patient shows a positive response to vasodilatation, high dose calcium channel blockers may be used. If these fail to lower PAH, in patients in NYHA class III, bosentan or prostanoids may be used; in NYHA class IV, epoprostenol alone or in combination with bosentan may then be employed. When all these treatments fail to control PAH, atrioseptostomy or, eventually, heart-lung transplantation may be considered. 3 6 THE LESSONS N In SSc, PAH is a severe complication that may rapidly lead to the patient's death; the early identification of PAH is mandatory to design a management plan to reduce pulmonary pressure (see fig 2) . N Cardiac Doppler echocardiography should be used regularly, including in asymptomatic patients; if a rise in pulmonary pressure is detected or, despite a negative Doppler echocardiography, a strong clinical suspicion for PAH exists, right catheterisation with vasoreactivity tests is mandatory to confirm PAH and to design the treatment.
N In cases of non-responsiveness to pharmacological vasoreactive treatments, a surgical approach (atrioseptotomy) should be considered. 9 N In the presence of alveolitis, CYC treatment 10-12 may be useful in order to control interstitial fibrosis (see fig 2) , which contributes to the genesis of PAH. The flow chart suggests the diagnostic procedure and the possible therapeutic options for PAH in SSc. PASP, pulmonary artery systolic pressure; PFT, pulmonary function tests; TLCO, carbon monoxide transfer factor; FVC, forced vital capacity; CCB, calcium channel blockers; ILD, interstitial lung disease; HRCT, high resolution computed tomography; CYC, cyclophosphamide; PAH, pulmonary arterial hypertension.
